Diabetes Mellitus and Associated Pharmacological Treatment

Running head: ENDOCRINE DISEASE
Name of the Student:
Name of the University:
Author note:

Introduction:
Over the decade, the predominance of diabetes mellitus type II affected a considerate
number if individuals in Australia. It is diabetes mellitus is a group of metabolic disorder
characterized by hyperglycemia which resulted from a defected secretion of insulin from the
body (Forslund et al., 2015). This paper will provide a summary of the diabetes mellitus and
associated pharmacological treatment.
Discussion:
Due to risk factors such as sedentary lifestyle, obesity, family history , Obesity,
prediabetic symptoms, glucose level increased in the blood because of glycogen metabolism
and the insulin-producing beta cells in the pancreases started secreting more insulin’s.
Consequently, cells become impaired to meet the demand of the body and Give rise to diabetes
mellitus and affected other organs. Diabetes dramatically increases the risk of heart disease,
diabetic retinopathy, and diabetic neuropathy (Rubino et al., 2016). The potential medications are
Biguanides (metformin), Thiazolidinedione (Rosiglitazone), Alpha-glucosidase inhibitors
( acarbose), Dopamine agonist), DPP-4 inhibitors. In the current context two most common and
potential treatment are metformin and Rosiglitazone. Metformin is biguanide anti-hyperglycemic
agent used for treating blood glucose level. It improves glycemic controls by decreasing hepatic
glucose. On the other hand, it is anti-diabetic drug in the thiazolidinedione class of drugs
(Courcoulas et al., 2015). It is administrated to the patient with type II diabetes mellitus in
combination with metformin. The study is highly relevant to the nursing practice since it will
also help nurses to provide safe and responsive care to the patient, support patient in self-care
management.